Impact of Primary Tumor Resection on Survival in High-Risk Neuroblastoma: A Long-Term Single-Center Study
This long-term single-center study of 64 high-risk neuroblastoma patients found no significant survival benefit from primary tumor resection compared to non-resection or incomplete resection, suggesting that favorable outcomes can be achieved without surgery and supporting individualized treatment strategies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the landscape of childhood cancers, few are as complex or as challenging as neuroblastoma. This disease begins in the nerve tissue of the developing body, often appearing as a mass in the abdomen or chest. While some forms of this cancer in very young children can vanish on their own or respond easily to treatment, a specific group known as high-risk neuroblastoma remains stubborn and dangerous. For decades, doctors have fought this aggressive form with a heavy arsenal: powerful chemotherapy drugs to shrink the tumor, radiation to zap remaining cells, and stem cell transplants to rebuild the immune system. A central question in this battle has been whether surgeons must also remove the original tumor entirely to give the child the best chance of survival. The prevailing wisdom in many parts of the world has leaned toward removing as much of the mass as possible, believing that a clean sweep offers the best protection against the cancer returning.
However, the reality of surgery is not always straightforward. These tumors often wrap themselves tightly around major blood vessels and vital organs, making a complete removal risky or even impossible without causing severe damage to the child. This creates a difficult dilemma for medical teams: is the risk of a major operation worth the potential reward, or can the cancer be controlled through other means? A team of researchers at Kyushu University in Japan set out to answer this question by looking back at over forty years of patient care. They examined the long-term outcomes of children treated for high-risk neuroblastoma, specifically comparing those who had their tumors completely removed against those who had only partial removal or no surgery at all. Their goal was to see if the extent of the surgery truly dictated who lived and who did not.
The researchers reviewed the medical records of 64 children treated at their center between 1985 and 2023. They divided these patients into groups based on what happened to the tumor: some had the entire mass removed, some had only part of it taken out, and a small number never underwent surgery. When they looked at the five-year survival rates, the results were surprising. The children who had their tumors completely removed did not live longer than those who had incomplete removal or no surgery at all. The survival rates were nearly identical, hovering around 53 to 57 percent for both groups. This finding held true even when the researchers looked at more recent patients treated with modern therapies, where the survival rates for those who skipped surgery were just as high as those who had it.
What mattered most, the study found, was not the surgeon's knife, but how the tumor responded to the initial chemotherapy. The researchers discovered that if a child's tumor shrank by more than 20 percent after the first round of drug treatment, their chances of survival improved significantly. This shrinkage was a strong signal that the cancer was sensitive to the medication and that the body was responding well to the systemic therapy. In contrast, the size of the tumor left behind after surgery, or whether surgery happened at all, did not change the outcome. In the group of children who did not have surgery, no one developed a new tumor in the exact spot where the original mass had been. Instead, when the cancer returned, it appeared in distant parts of the body, such as the bones, suggesting that the local control provided by radiation and drugs was sufficient to handle the primary site.
The authors suggest that their results might differ from other international studies because of how they used radiation therapy. In their protocol, any remaining tumor tissue received a relatively high dose of radiation, which may have been effective enough to kill off residual cancer cells without needing a complete surgical removal. This approach allowed them to avoid the dangers of operating on tumors that were entangled with critical structures. The study does not claim that surgery is useless for every patient, nor does it suggest that all high-risk neuroblastoma cases can be treated without an operation. Rather, it indicates that for a specific subset of patients, particularly those whose tumors shrink well with chemotherapy, a less aggressive surgical approach is a viable option. The findings support a more personalized strategy, where the decision to operate is based on the individual child's response to treatment and the specific risks involved, rather than a one-size-fits-all rule demanding total removal.
Ultimately, this long-term look at patient data offers a quiet but powerful shift in perspective. It suggests that the definition of a successful treatment for high-risk neuroblastoma does not necessarily require a scar-free abdomen or a perfectly clean surgical field. Instead, the key to survival appears to lie in the body's ability to respond to chemotherapy and the precision of radiation therapy. While the researchers acknowledge that their study is limited by its size and the fact that it was conducted at a single hospital, the consistency of their results over four decades is compelling. They conclude that future efforts should focus on identifying exactly which children can safely avoid major surgery, allowing medical teams to tailor their approach to spare young patients from unnecessary risks while still giving them the best possible chance at a long life.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.